ATE315645T1 - Dns oder gene, die an der parkinsonschen krankheit beteiligt sind - Google Patents

Dns oder gene, die an der parkinsonschen krankheit beteiligt sind

Info

Publication number
ATE315645T1
ATE315645T1 AT99902859T AT99902859T ATE315645T1 AT E315645 T1 ATE315645 T1 AT E315645T1 AT 99902859 T AT99902859 T AT 99902859T AT 99902859 T AT99902859 T AT 99902859T AT E315645 T1 ATE315645 T1 AT E315645T1
Authority
AT
Austria
Prior art keywords
disease
parkinson
dna
genes involved
sequence
Prior art date
Application number
AT99902859T
Other languages
English (en)
Inventor
Nobuyoshi Shimizu
Yoshikuni Mizuno
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Application granted granted Critical
Publication of ATE315645T1 publication Critical patent/ATE315645T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT99902859T 1998-02-09 1999-02-09 Dns oder gene, die an der parkinsonschen krankheit beteiligt sind ATE315645T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2753198 1998-02-09

Publications (1)

Publication Number Publication Date
ATE315645T1 true ATE315645T1 (de) 2006-02-15

Family

ID=12223704

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99902859T ATE315645T1 (de) 1998-02-09 1999-02-09 Dns oder gene, die an der parkinsonschen krankheit beteiligt sind

Country Status (10)

Country Link
US (2) US6716621B1 (de)
EP (1) EP1063294B1 (de)
JP (1) JP4430815B2 (de)
AT (1) ATE315645T1 (de)
AU (1) AU2299999A (de)
CA (1) CA2320220C (de)
DE (2) DE1063294T1 (de)
DK (1) DK1063294T3 (de)
ES (1) ES2257029T3 (de)
WO (1) WO1999040191A1 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2775984B1 (fr) * 1998-03-11 2006-09-15 Bioscreen Therapeutics Sa Criblage differentiel qualitatif
ATE315645T1 (de) * 1998-02-09 2006-02-15 Boehringer Ingelheim Int Dns oder gene, die an der parkinsonschen krankheit beteiligt sind
DK1131424T3 (da) * 1998-11-19 2009-11-23 Aventis Pharma Sa Mutationer af Pakin-genet, sammensætninger, fremgangsmåder samt anvendelser
CA2996759A1 (fr) 1998-11-19 2000-06-02 Aventis Pharma S.A. Mutations du gene de la parkine, compositions, methodes et utilisations
EP1081225A1 (de) * 1999-08-30 2001-03-07 Biofrontera Pharmaceuticals GmbH Transgenes Tiermodel für neurodegenerative Erkrankungen
EP1262557B1 (de) * 2000-02-24 2006-10-18 Boehringer Ingelheim International GmbH Das parkin-protein als ubiquitinligase
AU2001260140A1 (en) 2000-03-22 2001-10-03 Avntis Pharma Deutschland Gmbh Nematodes as model organisms for the investigation of neurodegenerative diseases, in particular parkinsons disease, uses and methods for the discovery of substances and genes which can be used in the treatment of the above disease states and identification of a nematode gene.
US7070940B2 (en) * 2002-07-18 2006-07-04 Aventis Pharma S.A. Method for determining the ability of a compound to modify the interaction between parkin and the p38 protein
US8506959B2 (en) 2002-11-01 2013-08-13 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
US8697082B2 (en) 2002-11-01 2014-04-15 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
US20080014194A1 (en) 2003-10-31 2008-01-17 Elan Pharmaceuticals, Inc. Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease
US9034337B2 (en) 2003-10-31 2015-05-19 Prothena Biosciences Limited Treatment and delay of outset of synucleinopathic and amyloidogenic disease
TW200509968A (en) 2002-11-01 2005-03-16 Elan Pharm Inc Prevention and treatment of synucleinopathic disease
US7358331B2 (en) 2003-05-19 2008-04-15 Elan Pharmaceuticals, Inc. Truncated fragments of alpha-synuclein in Lewy body disease
US7674599B2 (en) 2003-11-08 2010-03-09 Elan Pharmaceuticals, Inc. Methods of using antibodies to detect alpha-synuclein in fluid samples
JP5329434B2 (ja) 2007-01-31 2013-10-30 エラン・フアルマ・インターナシヨナル・リミテツド 新規基質を使用したパーキン活性のモジュレーターのアッセイ方法
US8147833B2 (en) 2007-02-23 2012-04-03 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
EP2118300B1 (de) 2007-02-23 2015-05-27 Prothena Biosciences Limited Verhinderung und behandlung synukleinopathischer und amyloidogener krankheiten

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE315645T1 (de) * 1998-02-09 2006-02-15 Boehringer Ingelheim Int Dns oder gene, die an der parkinsonschen krankheit beteiligt sind

Also Published As

Publication number Publication date
ES2257029T3 (es) 2006-07-16
EP1063294A1 (de) 2000-12-27
DE69929417T2 (de) 2006-08-03
DE69929417D1 (de) 2006-04-06
EP1063294A4 (de) 2002-01-16
EP1063294B1 (de) 2006-01-11
DK1063294T3 (da) 2006-05-22
AU2299999A (en) 1999-08-23
JP4430815B2 (ja) 2010-03-10
WO1999040191A1 (fr) 1999-08-12
DE1063294T1 (de) 2003-06-26
US6716621B1 (en) 2004-04-06
CA2320220A1 (en) 1999-08-12
US20050003385A1 (en) 2005-01-06
CA2320220C (en) 2011-08-02

Similar Documents

Publication Publication Date Title
DE69929417D1 (de) Dns oder gene, die an der parkinsonschen krankheit beteiligt sind
DK1013661T3 (da) 2'-O,4'-metylen bicyklonukleosid
ES2066760T3 (es) Nucleotidos de alquinilamino.
DE69840748D1 (de) Verfahren zur zubereitung von antisense oligonukleotiden
ATE277068T1 (de) 2'-modifizierte oligonucleotide mit rns wirkung, die konformell eingeschränkt sind
ATE374836T1 (de) Massenmarkierte hybridisierungssonden
ATE232880T1 (de) Neue nucleotidanaloga
DE69825253D1 (de) Verfahren für die herstellung von 1,1,1,3,3-pentafluorpropen und 2-chlor-pentafluorpropen
EP0950470A3 (de) Schleifwerkzeug und Verfahren zur Herstellung desselben
BR9912951A (pt) Método de fabricação de nucleotìdoes de 1,3-oxatiolano
ATE342911T1 (de) Synthese von nukleosiden und polynukleotiden
BR9908753B1 (pt) processo de hidroconversão integrado.
WO2001000661A3 (en) Carnitine carrier related protein-1
DE60026150D1 (de) Diagnostika und therapeutika für osteoporose
DE69816059D1 (de) Gen, das für das pyruvat dehydrogenase kinase von pflanzen kodiert
WO2000015785A3 (de) GENVERÄNDERUNG IM GEN FÜR DIE Gβ3-UNTEREINHEIT DES HUMANEN G-PROTEINS
ATE401403T1 (de) Nukleotidsequenzen, die an erhöhung oder verringerung von der ovulationsgeschwindigkeit in säugertieren beteiligt sind
DE69402201D1 (de) Phosphorhaltiges, metallurgisches silizium zur herstellung von organohalosilanen
NO995858L (no) Ny klasse kationiske nukleinsyre-overføringsmidler
DE59809600D1 (de) Doppelmetallcyanid-katalysatoren für die herstellung von polyetherpolyolen
ATE270331T1 (de) Rezeptor und dafür kodierendes nukleinsäuremolekül
EP1174522A3 (de) Tcf-1 Nukleotidsequenzvariation
BR9801379A (pt) Processo de preparação de dinitroanilinas dissubstituidas em 3,4
DE60238915D1 (de) Werkzeug zur herstellung dekorativer muster auf einem beschichtungsmaterial
BR9901948B1 (pt) processo de curtimento de couros com compostos carbonÍlicos.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1063294

Country of ref document: EP